Enhanced Radix Polygalae Extract Formulations for Improved ADHD Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept presents novel formulations and methods for treating attention-deficit hyperactivity disorder (ADHD) using Radix Polygalae extract, addressing the limitations of the original patent by enhancing efficacy, bioavailability, and personalized treatment options.
Background and Problem Solved
The original patent disclosed a method for treating ADHD using Radix Polygalae extract, but it had limitations in terms of efficacy, absorption, and individualized treatment. The new inventive concept addresses these limitations by introducing synergistic agents, liposomal formulations, omega-3 fatty acid combinations, personalized genetic profiling, and sustained-release dosage forms to provide more effective and targeted treatment options.
Detailed Description of the Inventive Concept
The new inventive concept encompasses five distinct approaches: (1) a system combining Radix Polygalae extract with a synergistic agent to enhance efficacy, (2) a liposomal formulation to increase bioavailability, (3) a composition combining Radix Polygalae extract with omega-3 fatty acids to potentiate therapeutic effects, (4) a method for personalized treatment using genetic profiling to optimize dosage, and (5) a sustained-release dosage form to provide consistent and prolonged therapeutic effects. These approaches overcome the limitations of the original patent and offer improved treatment options for ADHD patients.
Novelty and Inventive Step
The new inventive concept introduces novel combinations, formulations, and methods that are not obvious from the original patent. The use of synergistic agents, liposomal formulations, omega-3 fatty acid combinations, genetic profiling, and sustained-release dosage forms provides a significant improvement over the original patent, making the new inventive concept novel and non-obvious.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different synergistic agents, various liposomal formulations, and alternative combinations of omega-3 fatty acids. Additionally, the genetic profiling method could be adapted for use with other genetic markers or biomarkers. The sustained-release dosage form could be modified to provide different release profiles or combined with other therapeutic agents.
Potential Commercial Applications and Market
The enhanced Radix Polygalae extract formulations and methods have significant commercial potential in the pharmaceutical industry, particularly in the ADHD treatment market. The new inventive concept offers a competitive advantage in terms of efficacy, safety, and personalized treatment options, making it an attractive solution for patients, healthcare providers, and pharmaceutical companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/69 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K9/485 |
| A | A61 | A61K9/4825 |
| A | A61 | A61K9/4858 |
| A | A61 | A61K47/02 |
| A | A61 | A61K47/12 |
| A | A61 | A61P25/28 |
| A | A61 | A61K2236/333 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations for neurological disorders, specifically botanical extracts for ADHD treatment, encompassing drug delivery systems, pharmacological compositions, and personalized medicine approaches
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist with expertise in herbal medicine, drug formulation, neuropharmacology, and advanced drug delivery technologies, holding at least a PhD or equivalent professional experience in pharmaceutical research
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core invention, utilizing standard pharmaceutical techniques to enhance bioavailability, efficacy, and personalization of the Radix Polygalae extract for ADHD treatment. The disclosed modifications represent well-known strategies in pharmaceutical development, such as liposomal encapsulation, synergistic agent combinations, and genetic profiling for personalized dosing. These approaches would be considered routine optimization techniques within the pharmaceutical arts.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,592 |
|---|---|
| Title | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
| Assignee(s) | BioLite Inc. |